MYRIAD GENETICS INC
For the period ended Dec 31, 2024. Filed Feb 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 28, 2025
MYGN$5.67-1.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders' Equity for the Years Ended
Consolidated Statements of Stockholders’ Equity
| Commonstock | Additionalpaid-incapital | Accumulatedothercomprehensive loss | Accumulateddeficit | MyriadGenetics, Inc.Stockholders’equity | |
|---|---|---|---|---|---|
| BALANCES AT DECEMBER 31, 2021 | $0.8 | $1,226.3 | $(5.1) | $(254.2) | $967.8 |
| Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax | — | (4.3) | — | — | (4.3) |
| Stock-based compensation expense | — | 38.1 | — | — | 38.1 |
| Net loss | — | — | — | (112.0) | (112.0) |
| Other comprehensive loss, net of tax | — | — | (3.8) | — | (3.8) |
| BALANCES AT DECEMBER 31, 2022 | $0.8 | $1,260.1 | $(8.9) | $(366.2) | $885.8 |
| Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax | — | (2.8) | — | — | (2.8) |
| Issuance of common stock for public offering, net | 0.1 | 117.5 | — | — | 117.6 |
| Stock-based compensation expense | — | 40.7 | — | — | 40.7 |
| Net loss | — | — | — | (263.3) | (263.3) |
| Other comprehensive income, net of tax | — | — | 5.2 | — | 5.2 |
| BALANCES AT DECEMBER 31, 2023 | $0.9 | $1,415.5 | $(3.7) | $(629.5) | $783.2 |
| Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax | — | (7.5) | — | — | (7.5) |
| Stock-based compensation expense | — | 49.8 | — | — | 49.8 |
| Net loss | — | — | — | (127.3) | (127.3) |
| Other comprehensive income, net of tax | — | — | 2.9 | — | 2.9 |
| BALANCES AT DECEMBER 31, 2024 | $0.9 | $1,457.8 | $(0.8) | $(756.8) | $701.1 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.